Related Experiment Video

Updated: May 23, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies

Ragini Kudchadkar1, Kim H T Paraiso, Keiran S M Smalley

  • 1Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, FL 33612, USA.

Cancer Journal (Sudbury, Mass.)
|March 29, 2012
PubMed

Insights

Activating BRAF mutations are key in melanoma, leading to targeted therapies like vemurafenib. Research now focuses on overcoming BRAF inhibitor resistance for better metastatic melanoma treatment.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Activating BRAF mutations are found in approximately 50% of melanomas.
  • These mutations represent a significant turning point in treating disseminated melanoma.
  • BRAF mutations play a crucial role in melanoma initiation and progression.

Purpose of the Study:

  • To review the role of mutant BRAF in melanoma.
  • To discuss the development and approval of BRAF inhibitor vemurafenib.
  • To outline mechanisms of BRAF inhibitor resistance and strategies to overcome it.

Main Methods:

  • Review of the latest research on BRAF mutations in melanoma.
  • Discussion of the 10-year journey to vemurafenib approval.
  • Outline of findings on BRAF inhibitor resistance mechanisms.
  • Description of ongoing preclinical and clinical studies.

Main Results:

  • BRAF mutations are a critical factor in melanoma development.
  • Vemurafenib, a BRAF inhibitor, has been approved for metastatic melanoma treatment.
  • Understanding intrinsic and acquired resistance mechanisms is crucial.

Conclusions:

  • Targeting BRAF mutations has transformed melanoma therapy.
  • Overcoming BRAF inhibitor resistance is essential for durable responses.
  • Continued research in melanoma genetics and signaling inhibitors promises improved outcomes.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.